Date Hour Room Track
05th December,2018 11:00 am-12:30 pm Track 3

Investment in immunotherapy in 2018 is still attractive and sought out; what is its growth
potential after several years of being an investment blockbuster? What have been the 2018
investment successes in immunotherapy? Will immunotherapy disrupt the oncology market?
Are we at the growth, maturity, or saturation stage when we talk about investing in

Juan García - BioSeed Capital
Bram Vanparys - Gimv
Madiha Derouazi - AMAL Therapeutics
Khatereh Ahmadi - MSD
Chris Shelley - Penningtons Manches LLP

Continue your tour